Editor's Memo

Flight to Internet Implies HMOs Were 'Last Big Thing'


John Marcille

In Disney's charming "Beauty and the Beast," Maurice — the girl's father — is an eccentric inventor. (Wouldn't you, for once, just love to see a movie show a non-eccentric inventor? After all, some — Jefferson and Franklin, for instance — were practical enough to invent a nation without getting hanged in the process.)

Maurice's cleverness is just a tad out of sync. For instance, he invents a machine that automatically chops wood — just as the world is ready to move toward other sources of heat

Our cover story introduces some former high-powered managed care executives who have hurried toward the possibly greener pastures of e-health. In doing so, they hope to be on the cutting edge of great discovery — not left tinkering, like Maurice, on better ways to turn on gas street lights just as Edison comes out with his bulb.

These talented people decided to leave their six-figure jobs for opportunities to think outside the box; they are not afraid of failure. The story behind the story merits some discussion. It took Managed Care's editors about five minutes to come up with a half-dozen names. Just how many top executives have made this move, and whether that number can be called a trend, is impossible to determine. There is, however, something to be said for anecdotal evidence.

As the story points out, a possible motive for making this jump is a bit easier to pin down. As Michael Barrett of Forrester Research said, "Doctors are unhappy with health care at a time when the Internet beckons. It's got to be irresistible."

Having a sense of adventure adds to the "irresistibility" of e-health. Of course, it doesn't hurt to get results. J. D. Kleinke, a health care economist, isn't nostalgic for fee-for-service medicine, but he sees where the existing system is not making the grade. His e-health company specializes in getting drug information to doctors. (Q&A).

One way or another, e-health is going to be an adventure.

Now available

Precision medicine, big data, Alzheimer’s Disease, migraine, and RNA therapeutics.
Learnings from the April 2018 meeting.
Edited by Jill Condello, PhD, ICON Access, Commercialisation & Communications

UP NEXT